PLP (139-151)
CAS No. : 131334-43-5
| Size | Price | Stock |
|---|---|---|
| 1mg | $110 | In-stock |
| 5mg | $432 | In-stock |
| 10mg | $671 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-P0129 |
| M.Wt: | 1537.79 |
| Formula: | C72H104N20O16S |
| Purity: | >98 % |
| Solubility: | H2O : 100 mg/mL (ultrasonic) |
PLP (139-151) is amino acid residue 139 to 151 of myelin proteolipid protein (PLP) used to induce experimental autoimmune encephalomyelitis (EAE).
In Vitro:Severe clinical and histological EAE could be induced by adoptive transfer of the peptide-specific T cell line and 3 of 4 T cell clones. The T cell line/clones all responded strongly to PLP (139-151) in in vitro proliferative assays. Line SPL and all of the clones show strong proliferative response to the whole PLP molecule and to PLP (139-151)[1].
In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
PLP (139-151) can be used in animal modeling to create relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) models. The pro-inflammatory cytokine IL-17 plays a crucial role in the PLP (139-151)-induced encephalomyelitis process. After subcutaneous injection of PLP (139-151) into mice, CD4 cells that specifically respond to PLP (139-151) and release pro-inflammatory cytokines migrate to and accumulate in the damaged central nervous system (CNS) regions[4][5].
Administration: 100 μg • sc • single dose
2. One day after the subcutaneous injection of PLP (139-151), perform an intraperitoneal injection of 100 μl (2 ng/μl, dissolved in phosphate-buffered saline (PBS)) of Bordetella pertussis toxin (BPX) to further enhance the mouse's immune response to PLP (139-151).
3. Monitor the mice daily for changes in body weight and clinical status. Perform neurological evaluations using a clinical score (CS) system with the following scale: 0 for no abnormalities; 0.5 for a drooping tail tip; 1 for a limp tail; 1.5 for hind limb dysfunction; 2 for hind limb weakness; 2.5 for dragging hind limbs; 3 for hind limb paralysis; 3.5 for complete hind limb paralysis with the mouse unable to right itself when placed on its side; and 4 for complete hind limb paralysis and partial front limb paralysis.
4. Isolate mice with early clinical symptoms of encephalomyelitis in separate cages with easier access to food and water. Dehydrated mice should receive an intraperitoneal injection of saline solution at least once a day.
Histological Changes: Resulted iron deposits in the cerebellum, medulla, and spinal cord of the mice.
Molecular Changes: Enhanced the immune signals of TSPO and Iba1 (markers of microglia and macrophage activation) in immunohistochemical results, indicating that microglia and macrophages were activated.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- PLP (139-151)
- Cat. No.:
- HY-P0129
- Quantity:
Your information is safe with us.